Intra-Cellular Therapies(ITCI) - 2022 Q2 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenues for Q2 2022 were $55.6 million, a 178% increase from $20 million in Q2 2021 [8][47] - CAPLYTA net product revenues were $55.1 million, representing a 190% increase year-over-year and a 58% increase from Q1 2022 [9][48] - The net loss for Q2 2022 was $86.6 million, compared to a net loss of $68.7 million in Q2 2021 [51] Business Line Data and Key Metrics Changes - CAPLYTA new and total prescriptions increased by 225% and 191% respectively compared to Q2 2021, and by 55% and 51% respectively compared to Q1 2022 [11][41] - CAPLYTA is the first treatment indicated for depressive episodes associated with bipolar I or II disorder, leading to significant uptake in prescriptions [13][14] Market Data and Key Metrics Changes - CAPLYTA maintained over 98% coverage in Medicare Part D and Medicaid channels, with approximately 85% coverage in the commercial channel [44][110] - The company expects coverage to continue increasing in the coming months [110] Company Strategy and Development Direction - The company is expanding its clinical programs beyond schizophrenia and bipolar disorder to include major depressive disorder (MDD) and mixed features in MDD and bipolar depression [17][19] - Plans to file a supplemental new drug application with the FDA for lumateperone as an adjunctive therapy to antidepressants for MDD in 2024 [19] Management's Comments on Operating Environment and Future Outlook - Management remains confident in the ability to drive continued robust growth throughout 2022, with rising awareness levels among healthcare professionals [58][60] - The company acknowledges the impact of seasonal factors and COVID-19 on prescription trends but believes long-term trends remain healthy [68] Other Important Information - The company ended Q2 2022 with $679.2 million in cash and no debt [38] - The DTC campaign for CAPLYTA began in Q2 2022 and is expected to continue throughout the year, positively impacting prescription growth [85][87] Q&A Session Summary Question: Outlook on prescription trends and market penetration - Management is confident in continued robust growth and believes they have reached the majority of the target prescriber audience while still having room for additional reach [60] Question: Duration of the launch phase and inventory levels - Management indicated that the launch phase may extend closer to 12 months, with inventory levels remaining stable [68][70] Question: Impact of DTC campaign on growth - The DTC campaign has successfully targeted the bipolar depression audience, driving more visitors to the website and increasing patient requests for CAPLYTA [86] Question: Market penetration and brand awareness - Awareness levels among prescribers are where the company expects them to be, with significant room for upward penetration in both schizophrenia and bipolar depression markets [118][119] Question: Current sales split between bipolar depression and schizophrenia - The sales mix is increasingly leaning towards bipolar depression, with expectations to follow similar trends as existing branded products [141]